Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Gap Down on Disappointing Earnings

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) shares gapped down before the market opened on Wednesday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $1.06, but opened at $0.99. Tonix Pharmaceuticals shares last traded at $0.74, with a volume of 11,635,016 shares changing hands.

The company reported ($2.86) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.49) by ($1.37).

Separately, ValuEngine lowered shares of Tonix Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, March 9th.

The company has a debt-to-equity ratio of 0.01, a current ratio of 4.88 and a quick ratio of 4.88. The company’s 50-day simple moving average is $0.74 and its 200-day simple moving average is $1.04. The stock has a market capitalization of $48.74 million, a P/E ratio of -0.02 and a beta of 1.12.

Tonix Pharmaceuticals Company Profile (NASDAQ:TNXP)

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense. Its lead product candidate is Tonmyar (TNX-102 SL), a proprietary low-dose cyclobenzaprine and sublingual tablet as a bedtime administration, which is in Phase III development for the treatment of posttraumatic stress disorder (PTSD) and Fibromyalgia; and Phase II development for the treatment of agitation in Alzheimer's disease.

Read More: Real Estate Investment Trust (REIT) ETF

Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with's FREE daily email newsletter.